Lewis and Burke Announcements, Roundup & Funding Opportunities
Last Updated: 10/08/2026
Below are Lewis and Burke Announcement, Roundup and Funding Opportunities. Please read each carefully. Also, please reach out to Anthony Mayo in the Office of Research and Sponsored Programs for additional details orsp-preaward@newark.rutgers.edu
_______________________________________________________________
Funding Opportunity: ARPA-H Announces New SURPASS Program to Modernize Clinical Trials
The Advanced Research Projects Agency for Health (ARPA-H) recently announced its new Simulation-augmented, Real-time Platform Adaptive Seamless Trials (SURPASS) program which “aims to modernize today’s clinical trials so they can evaluate drugs and biologics faster, at lower cost, and with fewer participants than conventional approaches.” In particular, SURPASS will support projects that can establish sustainable, adaptive platforms that leverage predictive computational models, shared trial infrastructure, common control groups, and real-time analysis to improve decision-making and accelerate the drug development process.
ARPA-H will be hosting two optional opportunities to convene interested parties and provide a platform to ask questions and make connections. The first event is an informational webinar on October 15, 2026, with a registration deadline of October 12, 2026. ARPA-H will also be hosting a hybrid Proposer’s Day in Washington, DC on November 6, 2026, with a registration deadline of October 28, 2026. To register for one or both of these events, please find more information here.
Following these opportunities, a required Solution Summary will be due on November 30, 2026. ARPA-H will provide additional feedback to proposers before inviting full proposals due on January 22, 2027.
Funding Opportunity: NOAA Releases Coastal Flood Protection Research Program
The National Oceanic Atmospheric Administration (NOAA) recently released a new research program seeking to improve coastal flood protection through public-private partnerships, innovative insurance products, and improved sediment management. Solicited through NOAA’s National Centers for Coastal Ocean Science (NCCOS) Competitive Research Program, one to six projects are expected to be funded between $500,000 and $2 million per year, with no cost share required. With an estimated project start date of September 1, 2027, projects may be awarded up to four years, though shorter-term project proposals are encouraged. Successful projects will support state-of-the-art information and products to advance the use of natural infrastructure for coastal flood protection. Applications should address one or more of the following priority areas:
- Priority 1: Improve product delivery through the private sector
- Priority 2: Innovating insurance mechanisms for natural coastal flood defense
- Priority 3: Supporting sediment management practices
Eligibility is open to institutions of higher education, nonprofits, for-profits, state and local, and tribal governments, and federal applicants (including NOAA) which may receive funds from another agency. The funding opportunity details specific instructions for NOAA Cooperative Institute (NOAA) or Cooperative Ecosystem Study Unit (CESU) applicants. Multiorganizational partnerships are necessary to be competitive for the opportunity. Letters of intent are due to nccos.grant.awards@noaa.gov by November 9, 2026, with full applications due by February 12, 2027. An informational webinar on the solicitation will be offered on October 20, 2026, at 3:00 PM ET, with the meeting link to be posted here.
The full writeup is available here: Funding Opportunity – NOAA Releases Coastal Flood Protection Research Program.pdf
Engagement Opportunity: FDA Launches Nationwide Effort to Fill Advisory Committee Vacancies
On September 30, 2026, the U.S. Food and Drug Administration (FDA) announced a nationwide recruitment effort to bring 230 new scientific experts and consumer representatives to its advisory committees. These committees convene scientific experts such as physicians, researchers, and biostatisticians, as well as patient and consumer advocates, to evaluate evidence on FDA-regulated products and help the agency make informed decisions on behalf of the American public.
Candidates in numerous fields, such as oncology, cardiovascular medicine, neurology, genetics, medical devices, and others, are encouraged to submit applications through the FDA Advisory Committee Membership Nomination portal.
Nominees for scientific and technical positions must be able to demonstrate expertise in the subject matter topic of the relevant advisory committee. They must also be able to interpret complex scientific information, understand the public health significance of issues before the relevant committee, and possess the ability to provide objective and independent advice. Consumer representative nominees should be able to demonstrate affiliation with or participation in relevant consumer or community-based organizations, possess the ability to analyze technical data, weigh pros and cons, and evaluate product safety and efficacy from the perspective of the public. In addition to self-nominations, nominations may also be submitted by independent supporters on behalf of candidates, and there is no limit on the number of nominations or committees that may be submitted for.
All candidates for advisory committees will be required to submit a completed curriculum vitae; an acknowledgment and consent form; a written confirmation that the nominee is aware of the nomination (unless self-nominated); and for consumer representative applications, include a cover letter that lists consumer or community organizations for which the nominee can demonstrate active participation. Potential candidates will also be asked to provide detailed information concerning their financial holdings, employment, and research grants and/or contracts in order to determine potential conflicts of interest.
Nominees will be considered on a rolling basis for current and anticipated vacancies, although priority consideration will be given to consumer representative applications submitted by November 15, 2026, as well as to scientific and technical voting member positions submitted by November 30, 2026. Applications received after those dates will be considered for later vacancies as they arise. Members will serve terms of up to four years. Please find information below on specific FDA advisory committee vacancies that are currently available at the time of this notice’s writing, and the links include further information on expertise required for each vacancy:
- Blood, Vaccines, Biological Products Committee Vacancies
- Blood Products Advisory Committee – Seven Vacancies
- Cellular, Tissue and Gene Therapies Advisory Committee – Nine Vacancies
- Vaccines and Related Biological Products Advisory Committee – Ten Vacancies
- Drug Products Committee Vacancies
- Anesthetic and Analgesic Drugs Advisory Committee – Four Vacancies
- Antimicrobial Drugs Advisory Committee – Ten Vacancies
- Cardiovascular and Renal Drugs Advisory Committee – Three Vacancies
- Dermatologic and Ophthalmic Drugs Advisory Committee – Ten Vacancies
- Drug Safety and Risk Management Advisory Committee – Four Vacancies
- Endocrinologic and Metabolic Drugs Advisory Committee – Six Vacancies
- Genetic Metabolic Diseases Advisory Committee – Seven Vacancies
- Nonprescription Drugs Advisory Committee – Nine Vacancies
- Obstetrics, Reproductive, and Urologic Drugs Advisory Committee – Six Vacancies
- Oncologic Drugs Advisory Committee – Ten Vacancies
- Peripheral and Central Nervous System Drugs Committee – Three Vacancies
- Psychopharmacologic Drugs Advisory Committee – Six Vacancies
- Pulmonary-Allergy Drugs Advisory Committee – Four Vacancies
- Medical Devices and Radiation-Emitting Products Committee Vacancies
- Device Good Manufacturing Practice Advisory Committee – Nine Vacancies
- Technical Electronic Product Radiation Standards Advisory Committee – Fifteen Vacancies
- Medical Devices Advisory Committee
- Anesthesiology and Respiratory Therapy Devices Panel – Two Vacancies
- Circulatory System Devices Panel – Two Vacancies
- Clinical Chemistry and Clinical Toxicology Devices Panel – Five Vacancies
- Dental Products Devices Panel – Three Vacancies
- Ear, Nose and Throat Devices Panel – Two Vacancies
- Gastroenterology and Urology Devices Panel – Five Vacancies
- General and Plastic Surgery Devices Panel – Five Vacancies
- General Hospital and Personal Use Devices Panel – Five Vacancies
- Hematology and Pathology Devices Panel – Five Vacancies
- Immunology Devices Panel – Seven Vacancies
- Medical Devices Dispute Resolution Panel – Six Vacancies
- Microbiology Devices Panel – Seven Vacancies
- Molecular and Clinical Genetics Panel – Four Vacancies
- Neurological Devices Panel – Four Vacancies
- Obstetrics and Gynecology Devices Panel – Four Vacancies
- Ophthalmic Devices Panel – Seven Vacancies
- Orthopaedic and Rehabilitation Devices Panel – Four Vacancies
- Radiological Devices Panel – Five Vacancies
- Science Board to the FDA, Risk Communication, and Pediatrics Vacancies
- Science Board to the Food and Drug Administration – Fourteen Vacancies
- Pediatrics Advisory Committee – One vacancy
- Tobacco Advisory Committee Vacancies
- Tobacco Products Scientific Advisory Committee – One vacancy
Engagement Opportunities: Federal Advisory Committee Nomination Opportunities (September 28, 2026)
Please see the latest list of Federal Advisory Committee Nomination openings. Opportunities are currently available across the following committees:
- National Vaccine Advisory Committee, Department of Health and Human Services (HHS)
- National Geospatial Advisory Committee, US Geological Survey (USGS), Department of the Interior (DOI)
- Resource Advisory Councils (RACs), Bureau of Land Management (BLM), Department of the Interior (DOI)
- National Assessment Governing Board, National Center for Education Statistics (NCES), Department of Education (ED)
The full writeup is available here: Federal Advisory Committee Nomination Opportunities September 28, 2026.pdf
Policy Update: Executive Order on Disease-Carrying Pests
On September 29, President Trump signed an executive order, Eliminating Disease-Carrying Pests and Restoring Enjoyment of the Great Outdoors. It makes it federal policy to suppress tick and mosquito populations through non-chemical, technology-enabled approaches: habitat management, natural predators, sterile insect techniques, and biotechnology-based control tools. It also calls for better diagnosis, prevention, and treatment of diseases spread by ticks and mosquitoes, including Lyme disease, alpha-gal syndrome, West Nile, and dengue. The centerpiece is a Washington, D.C. demonstration. Within 60 days (on or about November 28), Interior, USDA, EPA, and GSA, consulting with HHS, must develop and launch a campaign to cut invasive mosquitoes (Asian tiger and Aedes aegypti) by 90 percent and ticks by 50 percent across D.C. by 2028. The campaign is meant to serve as a model for national expansion.
On the same timeline, EPA must deliver a regulatory framework for releasing sterilized, genetically modified, and bacteria-based control technologies into the environment. That framework is to draw on academic centers and industry and align with EO 14292 on biological research safety. EPA must also speed registration of new products it finds safe and effective. Within 90 days (on or about December 28), HHS and USDA must each issue prize competitions under 15 U.S.C. 3719 or direct research programs. HHS’s focus is diagnostics, preventives, and treatments, building on what the order calls the Lyme Disease Moonshot, plus a research agenda for alpha-gal immunotherapies. USDA’s focus is non-chemical control methods.
The EPA framework explicitly asks for input from academic centers. However, it goes directly to the President rather than through a public comment process, so the window for input is informal and short. Institutions and societies with expertise in vector biology, entomology, and biotechnology regulation should contact EPA, USDA, and HHS now. The D.C. campaign’s preference for commercial partners and cooperative agreements may open partnership opportunities for area institutions. Whether HHS and USDA choose prizes or research programs also matters: prizes reward results rather than fund the research behind them, which tends to favor product-ready teams over basic science. On funding, Section 3(f) only directs agencies to review available resources with OMB, and the order is subject to appropriations. Implementation will therefore likely draw on existing accounts, which could squeeze current research portfolios on these diseases.
The government is operating under a continuing resolution at largely current levels through December 11 (P.L. 119-103). The 90-day deliverables will therefore land during the post-election push to finish FY2027 funding. That is a window to seek report language that funds these priorities without displacing existing research. Researchers working on conventional insecticides, insecticide resistance, or gene drives should also note two things: the order’s emphasis on non-chemical methods, and that EPA’s framework goes to the President through the Homeland Security Advisor, under EO 14292’s biosafety framing.
|
||||||||||
|
||||||||||
|
||||||||||
|
||||||||||
|